QQQ   349.46 (+0.42%)
AAPL   178.98 (+0.98%)
MSFT   328.81 (+0.13%)
META   271.15 (+2.43%)
GOOGL   123.54 (+0.55%)
AMZN   121.83 (+1.04%)
TSLA   203.08 (-0.42%)
NVDA   390.66 (+3.26%)
NIO   7.33 (-2.66%)
BABA   82.28 (+3.43%)
AMD   118.49 (+0.24%)
T   15.75 (+0.13%)
F   12.08 (+0.67%)
MU   68.71 (+0.75%)
CGC   0.84 (+1.09%)
GE   103.94 (+2.37%)
DIS   88.31 (+0.40%)
AMC   4.59 (+2.00%)
PFE   38.15 (+0.34%)
PYPL   63.04 (+1.69%)
NFLX   400.81 (+1.41%)
QQQ   349.46 (+0.42%)
AAPL   178.98 (+0.98%)
MSFT   328.81 (+0.13%)
META   271.15 (+2.43%)
GOOGL   123.54 (+0.55%)
AMZN   121.83 (+1.04%)
TSLA   203.08 (-0.42%)
NVDA   390.66 (+3.26%)
NIO   7.33 (-2.66%)
BABA   82.28 (+3.43%)
AMD   118.49 (+0.24%)
T   15.75 (+0.13%)
F   12.08 (+0.67%)
MU   68.71 (+0.75%)
CGC   0.84 (+1.09%)
GE   103.94 (+2.37%)
DIS   88.31 (+0.40%)
AMC   4.59 (+2.00%)
PFE   38.15 (+0.34%)
PYPL   63.04 (+1.69%)
NFLX   400.81 (+1.41%)
QQQ   349.46 (+0.42%)
AAPL   178.98 (+0.98%)
MSFT   328.81 (+0.13%)
META   271.15 (+2.43%)
GOOGL   123.54 (+0.55%)
AMZN   121.83 (+1.04%)
TSLA   203.08 (-0.42%)
NVDA   390.66 (+3.26%)
NIO   7.33 (-2.66%)
BABA   82.28 (+3.43%)
AMD   118.49 (+0.24%)
T   15.75 (+0.13%)
F   12.08 (+0.67%)
MU   68.71 (+0.75%)
CGC   0.84 (+1.09%)
GE   103.94 (+2.37%)
DIS   88.31 (+0.40%)
AMC   4.59 (+2.00%)
PFE   38.15 (+0.34%)
PYPL   63.04 (+1.69%)
NFLX   400.81 (+1.41%)
QQQ   349.46 (+0.42%)
AAPL   178.98 (+0.98%)
MSFT   328.81 (+0.13%)
META   271.15 (+2.43%)
GOOGL   123.54 (+0.55%)
AMZN   121.83 (+1.04%)
TSLA   203.08 (-0.42%)
NVDA   390.66 (+3.26%)
NIO   7.33 (-2.66%)
BABA   82.28 (+3.43%)
AMD   118.49 (+0.24%)
T   15.75 (+0.13%)
F   12.08 (+0.67%)
MU   68.71 (+0.75%)
CGC   0.84 (+1.09%)
GE   103.94 (+2.37%)
DIS   88.31 (+0.40%)
AMC   4.59 (+2.00%)
PFE   38.15 (+0.34%)
PYPL   63.04 (+1.69%)
NFLX   400.81 (+1.41%)
NASDAQ:GMDA

Gamida Cell (GMDA) Stock Forecast, Price & News

$2.13
+0.03 (+1.43%)
(As of 10:46 AM ET)
Compare
Today's Range
$2.07
$2.13
50-Day Range
$0.68
$2.22
52-Week Range
$0.56
$3.66
Volume
363,206 shs
Average Volume
3.37 million shs
Market Capitalization
$158.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.60

Gamida Cell MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
261.9% Upside
$7.60 Price Target
Short Interest
Healthy
6.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Gamida Cell in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

476th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

71st out of 167 stocks


GMDA stock logo

About Gamida Cell (NASDAQ:GMDA) Stock

Gamida Cell Ltd. is a biotechnology company specializing in developing and commercializing innovative cell therapies. With a mission to transform the lives of patients with severe hematologic and solid tumor cancers, Gamida Cell is dedicated to harnessing the power of cell therapy to provide effective and personalized treatment options.

Headquartered in Jerusalem, Israel, Gamida Cell operates globally, focusing on developing and delivering breakthrough therapies to address significant unmet medical needs. The company's flagship product, Omidubicel, is an investigational advanced cell therapy designed to enhance the outcome of bone marrow transplantation and improve the standard of care for patients with hematologic malignancies.

Gamida Cell's products and services revolve around cell therapy, with a particular emphasis on expanding and enhancing the therapeutic potential of stem cells. By leveraging its proprietary NAM-based cell expansion technology platform, the company aims to increase the number and functionality of cells for transplantation, leading to improved patient outcomes.

The company primarily targets patients with blood cancers, including leukemia, lymphoma, and myeloma, where traditional treatment options often fall short. Gamida Cell's innovative approach has garnered recognition within the medical community and has received several notable achievements, milestones, and awards. For instance, in 2022, Gamida Cell was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for Omidubicel, highlighting the therapy's potential to address a critical medical need.

It is important to note that stock performance is influenced by various factors, including news and events specific to the company. Recent news or events that may have affected Gamida Cell's share price include the publication of clinical trial data, regulatory updates, and announcements regarding partnerships or collaborations.

Looking beyond Gamida Cell's specific performance, it is essential to consider the broader industry in which the company operates. The field of cell therapy has been gaining significant attention and investment in recent years, driven by advancements in technology and the potential to revolutionize the treatment of various diseases, including cancer. Gamida Cell operates in a competitive landscape, with several other companies developing cell therapies and vying for market share.

As part of the industry analysis, it is crucial to evaluate Gamida Cell's competitive positioning and advantages relative to its peers. The company's proprietary NAM-based cell expansion technology platform sets it apart from competitors and positions it as a leader in the field. This technology allows for the expansion and enhancement of cells for transplantation, improving treatment outcomes and addressing critical unmet needs.

Gamida Cell's partnerships and collaborations with established pharmaceutical companies provide validation and access to resources that enhance its competitive advantage. These collaborations enable the company to leverage the expertise and resources of its partners to accelerate the development and commercialization of its cell therapy products.

While Gamida Cell has demonstrated growth and potential, it has risks and challenges. The biotechnology industry is highly regulated, and regulation changes or the regulatory environment can impact the development and approval of new therapies. The company must navigate complex and evolving regulatory pathways to successfully bring its products to market.

Additionally, Gamida Cell faces the challenge of staying ahead of the competition in a rapidly evolving field. Other companies also invest in cell therapies, and competitors' breakthroughs could threaten Gamida Cell's market position. Maintaining a robust research and development pipeline, protecting intellectual property, and securing strategic partnerships are vital for the company's long-term success.

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Stock News Headlines

GMDA - Gamida Cell Ltd.
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Gamida Cell gets new finance chief
Gamida Cell (GMDA) Gets a Buy from H.C. Wainwright
ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
Gamida Cell Appoints Terry Coelho as CFO
Analyst Expectations for Gamida Cell's Future
Gamida Cell (NASDAQ:GMDA) Price Target Cut to $6.00
See More Headlines

GMDA Price History

GMDA Company Calendar

Last Earnings
3/27/2023
Today
6/01/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMDA
Fax
N/A
Employees
166
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.60
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+261.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-79,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.21) per share

Miscellaneous

Free Float
71,852,000
Market Cap
$156.20 million
Optionable
Not Optionable
Beta
1.62

Key Executives

  • Abigail L. Jenkins
    President, Chief Executive Officer & Director
  • Michele I. Korfin
    Chief Operating & Commercial Officer
  • Mary Theresa Coelho
    Chief Financial & Accounting Officer
  • Ronit Simantov
    Chief Medical & Scientific Officer
  • Yona Geffen
    Vice President-Research & Development













GMDA Stock - Frequently Asked Questions

Should I buy or sell Gamida Cell stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GMDA shares.
View GMDA analyst ratings
or view top-rated stocks.

What is Gamida Cell's stock price forecast for 2023?

5 analysts have issued twelve-month price targets for Gamida Cell's stock. Their GMDA share price forecasts range from $6.00 to $11.00. On average, they expect the company's stock price to reach $7.60 in the next year. This suggests a possible upside of 261.9% from the stock's current price.
View analysts price targets for GMDA
or view top-rated stocks among Wall Street analysts.

How have GMDA shares performed in 2023?

Gamida Cell's stock was trading at $1.29 on January 1st, 2023. Since then, GMDA shares have increased by 62.8% and is now trading at $2.10.
View the best growth stocks for 2023 here
.

Are investors shorting Gamida Cell?

Gamida Cell saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 4,960,000 shares, a drop of 39.5% from the April 30th total of 8,200,000 shares. Based on an average daily volume of 5,050,000 shares, the days-to-cover ratio is presently 1.0 days.
View Gamida Cell's Short Interest
.

When is Gamida Cell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our GMDA earnings forecast
.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd. (NASDAQ:GMDA) posted its earnings results on Monday, March, 27th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.05.

What other stocks do shareholders of Gamida Cell own?
When did Gamida Cell IPO?

(GMDA) raised $50 million in an IPO on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Who are Gamida Cell's major shareholders?

Gamida Cell's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (9.07%), BlackRock Inc. (0.20%), Leavell Investment Management Inc. (0.19%), Jane Street Group LLC (0.07%), Susquehanna International Group LLP (0.00%) and Virtu Financial LLC (0.04%). Insiders that own company stock include Abigail L Jenkins and Stephen T Wills.
View institutional ownership trends
.

How do I buy shares of Gamida Cell?

Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $2.10.

How much money does Gamida Cell make?

Gamida Cell (NASDAQ:GMDA) has a market capitalization of $156.20 million. The company earns $-79,380,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How many employees does Gamida Cell have?

The company employs 166 workers across the globe.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for the company is www.gamida-cell.com. The company can be reached via phone at (713) 400-6400 or via email at irpr@gamida-cell.com.

This page (NASDAQ:GMDA) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -